These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 7691308)

  • 1. Treatment of poor prognosis non-Hodgkin's lymphoma with intensive, inpatient combination chemotherapy of brief duration: long-term followup.
    Waits TM; Greco FA; Greer JP; Hainsworth JD
    Leuk Lymphoma; 1993 Aug; 10(6):453-9. PubMed ID: 7691308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma.
    McMaster ML; Greer JP; Wolff SN; Johnson DH; Greco FA; Stein RS; Cousar JB; Flexner JM; Hainsworth JD
    Cancer; 1991 Jul; 68(2):233-41. PubMed ID: 1712662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy.
    Waits TM; Greco FA; Greer JP; Johnson DH; Wolff SN; Stein RS; McMaster ML; Hainsworth JD
    J Clin Oncol; 1993 May; 11(5):943-9. PubMed ID: 7683712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma.
    McMaster ML; Johnson DH; Greer JP; Wolff SN; Hildreth CR; Greco FA; Hainsworth JD
    Cancer; 1991 Mar; 67(6):1487-92. PubMed ID: 1705861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    Ann Oncol; 1994; 5 Suppl 2():91-5. PubMed ID: 7515652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
    Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
    Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
    Sweetenham JW; Mead GM; Whitehouse JM
    J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective treatment of small-noncleaved-cell lymphoma with high-intensity, brief-duration chemotherapy.
    McMaster ML; Greer JP; Greco FA; Johnson DH; Wolff SN; Hainsworth JD
    J Clin Oncol; 1991 Jun; 9(6):941-6. PubMed ID: 1709685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The response of diffuse large cell and other intermediate grade non-Hodgkin's lymphomas to adriamycin containing combination chemotherapy.
    Lishner M; Slingerland J; Theresa C; Sutcliffe SB
    Leuk Lymphoma; 1994 Mar; 13(1-2):131-6. PubMed ID: 7517744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicentre combined chemotherapy protocol for large cell advanced non Hodgkin's lymphoma.
    Dumont J; Charpy-Validire P; Mosseri V; Gabarre J; Belanger C; Turpin F; Binet JL; Dreyfus F; Fourquet A; Janvier M
    Hematol Oncol; 1991; 9(4-5):197-207. PubMed ID: 1720759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
    Longo DL; Duffey PL; Jaffe ES; Raffeld M; Hubbard SM; Fisher RI; Wittes RE; DeVita VT; Young RC
    J Clin Oncol; 1994 Oct; 12(10):2153-9. PubMed ID: 7523607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
    Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
    J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparable prognostic factors and survival in elderly patients with aggressive non-Hodgkin's lymphoma treated with standard-dose adriamycin-based regimens.
    Grogan L; Corbally N; Dervan PA; Byrne A; Carney DN
    Ann Oncol; 1994; 5 Suppl 2():47-51. PubMed ID: 7515647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851.
    Gottlieb AJ; Anderson JR; Ginsberg SJ; Bloomfield CD; Norton L; Barcos M; Peterson BA; Nissen N; Henderson ES; Holland JF
    Cancer; 1990 Nov; 66(9):1888-96. PubMed ID: 1699653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
    J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The place of third-generation regimens in the treatment of adult aggressive non-Hodgkin's lymphoma.
    Armitage JO
    Ann Oncol; 1991 Jan; 2 Suppl 1():37-41. PubMed ID: 1710488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Santini G; Salvagno L; Leoni P; Chisesi T; De Souza C; Sertoli MR; Rubagotti A; Congiu AM; Centurioni R; Olivieri A; Tedeschi L; Vespignani M; Nati S; Soracco M; Porcellini A; Contu A; Guarnaccia C; Pescosta N; Majolino I; Spriano M; Vimercati R; Rossi E; Zambaldi G; Mangoni L; Rizzoli V
    J Clin Oncol; 1998 Aug; 16(8):2796-802. PubMed ID: 9704732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
    Lee EJ; Petroni GR; Schiffer CA; Freter CE; Johnson JL; Barcos M; Frizzera G; Bloomfield CD; Peterson BA
    J Clin Oncol; 2001 Oct; 19(20):4014-22. PubMed ID: 11600602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.